Bioluminescence Resonance Energy Transfer as a Screening Assay: Focus on Partial and Inverse Agonism

Abstract

The reported data for compound screening with the bioluminescence resonance energy transfer (BRET²) assay is very limited, and several questions remain unaddressed, such as the behavior of agonists. Eleven β2 adrenergic receptor (β2-AR) agonists were tested for full or partial agonism in an improved version of the receptor/β-arrestin2 BRET² assay and in 2 cyclic adenosine monophosphate (cAMP) assays (column cAMP assay and ALPHAscreen™ cAMP assay). Tested in the highly sensitive ALPHAscreen™ cAMP assay, all selected agonists behaved as full agonists, using isoproterenol as a reference compound. In the less sensitive column cAMP assay, ephedrine and dopamine had a clear partial response. For the BRET² assay, a highly graded picture was obtained. Moreover, β2-AR antagonists were tested for inverse agonism. Pronounced inverse agonism was detected in the ALPHAscreen™ cAMP assay. Only marginal inverse agonistic responses were seen for alprenolol and pindolol in the column cAMP assay, and no inverse agonism was seen in the BRET² assay. For the β2-AR, the BRET² assay may be superior for secondary screening of agonists where a separation of full and partial agonists is needed and the ALPHAscreen™ cAMP assay may be preferred for primary screening of agonists where all receptor activating compounds are desired.

Keywords

β2 adrenergic receptor BRET assay cAMP assay constitutive activity partial agonism inverse agonism

References

Hemmila IA , Hurskainen P : Novel detection strategies for drug discovery. Drug Discov Today 2002;7:S150-S156.

Kostenis E : Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci 2001;22:560-564.

Angers S , Salahpour A , Bouvier M : Dimerization: an emerging concept for G protein–coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002;42:409-435.

Azzi M , Charest PG , Angers S , Rousseau G , Kohout T , Bouvier M , et al: β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein–coupled receptors. Proc Natl Acad Sci U S A 2003;100:11406-11411.

Vrecl M , Jorgensen R , Pogacnik A , Heding A : Development of a BRET2 screening assay using β-arrestin 2 mutants. J Biomol Screen 2004;9:322-333.

Claing A , Laporte SA , Caron MG , Lefkowitz RJ : Endocytosis of G protein–coupled receptors: roles of G protein–coupled receptor kinases and β-arrestin proteins. Prog Neurobiol 2002;66:61-79.

Perry SJ , Lefkowitz RJ : Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002;2:130-138.

Lefkowitz RJ : G protein–coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 1998;273:18677-18680.

Luttrell LM , Lefkowitz RJ : The role of β-arrestins in the termination and transduction of G-protein–coupled receptor signals. J Cell Sci 2002;115: 455-465.

10.

Luttrell LM : “Location, location, location”: activation and targeting of MAP kinases by G protein–coupled receptors. J Mol Endocrinol 2003;30:117-126.

11.

Oakley RH , Laporte SA , Holt JA , Caron MG , Barak LS : Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein–coupled receptors delineate two major classes of receptors. J Biol Chem 2000;275: 17201-17210.

12.

Boute N , Jockers R , Issad T : The use of resonance energy transfer in high-throughput screening: BRET versus FRET. Trends Pharmacol Sci 2002;23:351-354.

13.

Heding A : Use of the BRET 7TM receptor/β-arrestin assay in drug discovery and screening. Expert Rev Mol Diagn 2004;4:403-411.

14.

Hoffmann C , Leitz MR , Oberdorf-Maass S , Lohse MJ , Klotz KN : Comparative pharmacology of human β-adrenergic receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004;369:151-159.

15.

Guimaraes S , Moura D : Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-356.

16.

Kotlikoff MI , Kamm KE : Molecular mechanisms of β-adrenergic relaxation of airway smooth muscle. Annu Rev Physiol 1996;58:115-141.

17.

Swaminath G , Xiang Y , Lee TW , Steenhuis J , Parnot C , Kobilka BK : Sequential binding of agonists to the β2 adrenoceptor: kinetic evidence for intermediate conformational states. J Biol Chem 2004;279:686-691.

18.

van der Woude HJ , Aalbers R : Long-acting β2-agonists: comparative pharmacology and clinical outcomes. Am J Respir Med 2002;1:55-74.

19.

Oakley RH , Hudson CC , Cruickshank RD , Meyers DM , Payne RE , Rhem SM , et al: The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein–coupled receptors. Assay Drug Dev Technol 2002;1:21-30.

20.

Jorgensen J , Martini L , Schwartz TW , Elling CE : Characterization of glucagon-like peptide-1 receptor β-arrestin2 interaction: a high-affinity receptor phenotype. Mol Endocrinol 2005;19:812-823.

21.

McGraw DW , Liggett SB : Heterogeneity in β-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the β2-adrenergic receptor. J Biol Chem 1997;272:7338-7344.

22.

Tran TM , Friedman J , Qunaibi E , Baameur F , Moore RH , Clark RB : Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein–coupled receptor kinase phosphorylation of the β2-adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol 2004; 65:196-206.

23.

Anderson GP : Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145-2160.

24.

Ball DI , Brittain RT , Coleman RA , Denyer LH , Jack D , Johnson M , et al: Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991;104:665-671.

25.

January B , Seibold A , Allal C , Whaley BS , Knoll BJ , Moore RH , et al: Salmeterol-induced desensitization, internalization and phosphorylation of the human β2-adrenoceptor. Br J Pharmacol 1998;123:701-711.